Join us now
The Calcitonin Gene-Related Peptide (CGRP) Forum has been established by an international group of clinicians and researchers. It provides all healthcare professionals with open and free access to independent news, information, comment and resources about the exciting potential of CGRP as a novel therapeutic target for the prevention of migraine in millions of people worldwide.
Why are new migraine treatments needed?
Migraine is the third most common disease worldwide and current treatments are often ineffective and poorly tolerated.
Read more Become a member
Why is CGRP an important therapeutic target?
Multiple lines of evidence support a role for CGRP in migraine pathophysiology.
Its blockade is now a potentially important therapeutic target for migraine prevention.
Read more Become a member
New Hot Topic
What do physicians in Canada need to know about anti-CGRP therapies?
In Canada, Aimovig (erenumab) is currently the only approved CGRP antibody but Emgality (galcanezumab) and Ajovy (fremanezumab) are being considered by Health Canada and are expected to be available at the end of 2019 or early 2020.
Read More